Alimera Sciences announced today that a new trial that has commenced with pSivida’s Medidur for age-related macular edema (AMD). Per the revised agreement with Alimera, Alimera is funding the trial, and pSivida will get 20 percent of any profits down the line. more

Certainly, it’s important to keep up with the earnings on the Big Dogs, but it’s always more fun to check in on what’s happening when the Pioneers report.
more

The following originally appeared in my complementary e-zine, Nanotech Investing News.
more

The following originally appeared in my complementary e-zine, Nanotech Investing News.
more

It’s been reported by various sources today that Motorola has begun the Great Reshuffle of its mobile phone division.
more

Development-stage drug delivery maker pSivida announced today that it intends to reincorporate its operations to its Boston office. The move is intended to expand its visibility—and liquidity—in the US market.
more